2025 PRIMO | Major Endocrine and Targeted Therapy Advances In the Treatment of HR+/HER2- Breast Cancer

2025 PRIMO | Major Endocrine and Targeted Therapy Advances In the Treatment of HR+/HER2- Breast Cancer

0% Complete

Course Content

This material is non-CME, no credits are available, and a certificate will not be provided upon completion.

Course Details

Duration
0.00 hour
Released
May 14, 2025
Last Review
May 14, 2025
Expires
May 14, 2028

Faculty & Disclosure

Faculty

Vicente Valero, MD, FACP

Disclosure

Vicente Valero, MD, FACP discloses no such relationships exist

Accreditation

NA